Budesonide NDC 0093-6817

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-6817Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-6817Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0093-6817-73	00093681773	6 POUCH in 1 CARTON (0093-6817-73) / 5 AMPULE in 1 POUCH (0093-6817-45) / 2 mL in 1 AMPULE (0093-6817-19)Marketed from Mar 11, 2016

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Budesonide
Generic name (nonproprietary): budesonide
Active ingredients: Budesonide — 1 mg/2mL
Dosage form: Suspension
Route: Respiratory (Inhalation)
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204548
Marketing start: Mar 11, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 0093-6817_e505244f-d53f-4dc0-acd7-45dc98034b97SPL ID e505244f-d53f-4dc0-acd7-45dc98034b97SPL set ID d90ffda1-12c7-4726-90e9-64bb103e84b5RxCUI 252559UNII Q3OKS62Q6XUPC 0300936817735
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400093681773 followed by a unit qualifier and the quantity

Package 00093-6817-73. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 31, 2019.

Indications (excerpt from the label)

Budesonide inhalation suspension is an inhaled corticosteroid indicated for: Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Maintenance Treatment of Asthma Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Limitations of Use: Budesonide inhalation suspension is NOT indicated for the relief of acute bronchospasm.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)